share_log

Xenon Pharmaceuticals Insiders Sell US$4.5m Of Stock, Possibly Signalling Caution

Xenon Pharmaceuticals Insiders Sell US$4.5m Of Stock, Possibly Signalling Caution

Xenon Pharmicals内部人士出售了450万美元的股票,这可能表明谨慎行事
Simply Wall St ·  05/13 08:03

Over the past year, many Xenon Pharmaceuticals Inc. (NASDAQ:XENE) insiders sold a significant stake in the company which may have piqued investors' interest.   When analyzing insider transactions, it is usually more valuable to know whether insiders are buying versus knowing if they are selling, as the latter sends an ambiguous message.  However, shareholders should take a deeper look if several insiders are selling stock over a specific time period.    

在过去的一年中,许多Xenon Pharmicals Inc.(纳斯达克股票代码:XENE)内部人士出售了该公司的大量股份,这可能激起了投资者的兴趣。在分析内幕交易时,了解内部人士是否在买入通常比知道他们是否在卖出更有价值,因为后者发出的信息模棱两可。但是,股东应更深入地研究是否有几位内部人士在特定时间段内出售股票。

While insider transactions are not the most important thing when it comes to long-term investing,  logic dictates you should pay some attention to whether insiders are buying or selling shares.

尽管内幕交易并不是长期投资中最重要的事情,但逻辑表明,你应该注意内部人士是在买入还是卖出股票。

The Last 12 Months Of Insider Transactions At Xenon Pharmaceuticals

Xenon Pharmicals 过去 12 个月的内幕交易

Over the last year, we can see that the biggest insider sale was by the Chairman of the Board, Simon Pimstone, for US$1.9m worth of shares, at about US$39.90 per share.    That means that an insider was selling shares at below the current price (US$40.54).  When an insider sells below the current price, it suggests that they considered that lower price to be fair. That makes us wonder what they think of the (higher) recent valuation.  While insider selling is not a positive sign, we can't be sure if it does mean insiders think the shares are fully valued, so it's only a weak sign.   We note that the biggest single sale was 89% of Simon Pimstone's holding.    

在过去的一年中,我们可以看到,最大规模的内幕出售是董事会主席西蒙·皮姆斯通出售的价值190万美元的股票,每股约39.90美元。这意味着一位内部人士正在以低于当前价格(40.54美元)的价格出售股票。当内部人士以低于当前价格的价格出售时,这表明他们认为较低的价格是公平的。这让我们想知道他们如何看待最近(更高的)估值。尽管内幕抛售不是一个积极的信号,但我们无法确定这是否意味着内部人士认为股票已完全估值,因此这只是一个弱势信号。我们注意到,最大的单笔出售是西蒙·皮姆斯通持股的89%。

All up, insiders sold more shares in Xenon Pharmaceuticals than they bought, over the last year.    The chart below shows insider transactions (by companies and individuals) over the last year.  By clicking on the graph below, you can see the precise details of each insider transaction!

总而言之,去年内部人士出售的Xenon Pharmicals股票比他们买入的还要多。下图显示了去年的内幕交易(公司和个人)。通过点击下面的图表,你可以看到每笔内幕交易的确切细节!

NasdaqGM:XENE Insider Trading Volume May 13th 2024

纳斯达克通用汽车:XENE 内幕交易量 2024 年 5 月 13 日

I will like Xenon Pharmaceuticals better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

如果我看到一些重大的内幕收购,我会更喜欢Xenon Pharmicals。在我们等待的同时,请查看这份免费清单,列出了最近有大量内幕收购的成长型公司。

Xenon Pharmaceuticals Insiders Are Selling The Stock  

Xenon Pharmicals内部人士正在出售该股票

Over the last three months, we've seen notably more insider selling, than insider buying, at Xenon Pharmaceuticals.  In total,   Independent Director  Steven Gannon  sold US$1.3m worth of shares in that time.  Meanwhile   Executive Vice President of Strategy & Innovation  Robin Sherrington  bought US$12k worth , as we said above .   We don't view these transactions as a positive sign.    

在过去的三个月中,我们看到Xenon Pharmicals的内幕卖出明显多于内幕买入。独立董事史蒂芬·甘农当时总共出售了价值130万美元的股票。同时,正如我们上面所说,战略与创新执行副总裁罗宾·谢灵顿购买了价值1.2万美元的股票。我们不认为这些交易是积极的信号。

Does Xenon Pharmaceuticals Boast High Insider Ownership?

Xenon Pharmicals拥有很高的内部所有权吗?

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own.  A high insider ownership often makes company leadership more mindful of shareholder interests.   From our data, it seems that Xenon Pharmaceuticals insiders own 0.3% of the company, worth about US$8.3m.  Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!  

测试公司领导者与其他股东之间一致性的另一种方法是查看他们拥有多少股份。较高的内部所有权通常会使公司领导层更加关注股东的利益。从我们的数据来看,Xenon Pharmicals内部人士似乎拥有该公司0.3%的股份,价值约830万美元。总的来说,这种所有权水平并不那么令人印象深刻,但肯定总比没有好!

So What Do The Xenon Pharmaceuticals Insider Transactions Indicate?

那么,Xenon Pharmicals的内幕交易表明了什么?

The stark truth for Xenon Pharmaceuticals is that there has been more insider selling than insider buying in the last three months.     Despite some insider buying, the longer term picture doesn't make us feel much more positive.    Insiders own relatively few shares in the company, and when you consider the sales, we're not particularly excited about the stock.  So we'd only buy after very careful consideration.      So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing.    For instance, we've identified 4 warning signs for Xenon Pharmaceuticals (1 is concerning) you should be aware of.  

对Xenon Pharmicals来说,严峻的事实是,在过去的三个月中,内幕卖出比内幕买入还多。尽管有一些内幕买盘,但长期前景并不能使我们感到更加乐观。内部人士拥有该公司的股票相对较少,当你考虑销售情况时,我们对这只股票并不特别兴奋。因此,我们只有在经过仔细考虑后才会购买。因此,虽然了解内部人士在买入或卖出方面的所作所为很有帮助,但了解特定公司面临的风险也很有帮助。例如,我们已经确定了Xenon Pharmicals的4个警告信号(其中一个令人担忧),你应该注意。

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

如果你想看看另一家公司——一家财务状况可能优越的公司——那么千万不要错过这份免费的股本回报率高、债务低的有趣公司的名单。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,内部人士是指向相关监管机构报告其交易的个人。我们目前只考虑公开市场交易和私下处置的直接利益,不包括衍生品交易或间接权益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧吗?请直接联系我们。或者,也可以发送电子邮件至编辑团队 (at) simplywallst.com。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发